CoChat

Effects of repeated phencyclidine administration on adult hippocampal neurogenesis in the rat

Liu, Juan, Suzuki, Toshihito, Seki, Tatsunori, Namba, Takashi, Tanimura, Atsushi, Arai, Heii · 2006 · Synapse
Cited by 52

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Dysfunctional maturation of neural networks, particularly hippocampus-prefrontal networks, may be of particular interest in determining the pathophysiology of schizophrenia. Phencyclidine (PCP)-induced symptoms in humans appear to offer a more complete model of schizophrenia than do amphetamine-induced symptoms. This study investigated the effects of intermittent i.p. injections of PCP (7.5 mg/kg) on cell proliferation and survival of granule cells in the dentate gyrus of the rat brain using quantitative immunohistochemical techniques for 5-bromo-2'-deoxyuridine (BrdU)-positive cells. After repeated PCP injection for 14 days, mean scores for stereotyped behavior increased with the number of injections, while scores for ataxia and backpedaling as serotonergic behaviors gradually decreased. The number of BrdU-positive cells decreased by 23% in the subgranular zone of the dentate gyrus by 24 h after repeated injections. However, decreased levels of BrdU-positive cells returned to control levels within 1 week. Differentiation of newly formed cells was not influenced. Repeated PCP administration after BrdU injection did not exert any effects on survival of newly generated cells. These findings suggest that transient disturbances of cell proliferation in the dentate gyrus occur under PCP-related behavioral abnormalities. Whether disturbed cell proliferation would thus be closely implicated in the development of behavioral sensitization induced by PCP administration is unclear, but this would possibly result from adaptation to new pharmacological conditions under behavioral sensitization or stressful conditions of PCP-related abnormal behaviors. Further studies are required to elucidate the biological significance of hippocampal neurogenesis in the mechanisms underlying the development of cognitive dysfunctions and the psychosis of schizophrenia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/syn.20275

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 80

  1. Abe, 2001, Neuropsychopharmacology, 25, 173, 10.1016/S0893-133X(00)00250-5 · DOI
  2. Abe, 2005, Prog Neuropsychopharmacol Biol Psychiatry, 29, 133, 10.1016/j.pnpbp.2004.10.015 · DOI
  3. Adams, 1998, J Neurosi, 18, 5545
  4. Arvidsson, 2001, Eur J Neurosci, 14, 10, 10.1046/j.0953-816x.2001.01611.x · DOI · Paper page
  5. Banasr, 2004, Neuropsychopharmacology, 29, 450, 10.1038/sj.npp.1300320 · DOI · Paper page
  6. Becker, 2003, Prog Neuropsychopharmacol Biol Psychiatry, 27, 687, 10.1016/S0278-5846(03)00080-0 · DOI · Paper page
  7. Benes, 1999, Biol Psychiatry, 46, 589, 10.1016/S0006-3223(99)00136-5 · DOI · Paper page
  8. Brezun, 1999, Neuroscience, 89, 999, 10.1016/S0306-4522(98)00693-9 · DOI · Paper page
  9. Brezun, 2000, Eur J Neurosci, 12, 391, 10.1046/j.1460-9568.2000.00932.x · DOI · Paper page
  10. Cameron, 1994, Neuroscience, 61, 203, 10.1016/0306-4522(94)90224-0 · DOI · Paper page
  11. Cameron, 1995, J Neurosci, 15, 4687, 10.1523/JNEUROSCI.15-06-04687.1995 · DOI · Paper page
  12. Carlezon, 2002, Trends Neurosci, 25, 610, 10.1016/S0166-2236(02)02289-0 · DOI · Paper page
  13. Castellani, 1981, Eur J Pharmacol, 73, 143, 10.1016/0014-2999(81)90086-8 · DOI
  14. Castner, 2004, Psychopharmacology, 174, 111, 10.1007/s00213-003-1710-9 · DOI · Paper page
  15. Conn, 1997, Annu Rev Pharmacol Toxicol, 37, 205, 10.1146/annurev.pharmtox.37.1.205 · DOI · Paper page
  16. Corso, 1997, Brain Res, 752, 1, 10.1016/S0006-8993(96)01347-9 · DOI
  17. Dawirs, 2001, Acta Psychiatr Scand, 104, 10, 10.1034/j.1600-0447.2001.104s408010.x · DOI
  18. Druhan, 1999, Behav Brain Res, 102, 195, 10.1016/S0166-4328(99)00017-0 · DOI
  19. Duncan, 2001, Neuropsychopharmacology, 25, 72, 10.1016/S0893-133X(00)00240-2 · DOI
  20. Eisch, 2002, Prog Brain Res, 138, 315, 10.1016/S0079-6123(02)38085-3 · DOI
  21. Emsley, 2005, Prog Neurobiol, 75, 321, 10.1016/j.pneurobio.2005.04.002 · DOI · Paper page
  22. Feron, 1999, Schizophr Res, 40, 211, 10.1016/S0920-9964(99)00055-9 · DOI
  23. Gasbarri, 1994, Brain Res Bull, 33, 445, 10.1016/0361-9230(94)90288-7 · DOI · Paper page
  24. Gould, 1992, J Neurosci, 12, 3642, 10.1523/JNEUROSCI.12-09-03642.1992 · DOI · Paper page
  25. Halim, 2004, Neuropsychopharmacology, 29, 1063, 10.1038/sj.npp.1300422 · DOI · Paper page
  26. Hanania, 1999, Synapse, 31, 229, 10.1002/(SICI)1098-2396(19990301)31:3<229::AID-SYN8>3.0.CO;2-3 · DOI
  27. Harrison, 2001, Hippocampus, 11, 508, 10.1002/hipo.1067 · DOI · Paper page
  28. Hayase, 2002, Pharmacol Biochem Behav, 71, 19, 10.1016/S0091-3057(01)00585-8 · doi:10.1016/s0091-3057(01)00585-8
  29. Heckers, 2002, J Neural Transm, 109, 891, 10.1007/s007020200073 · DOI · Paper page
  30. Heidbreder, 1996, Synapse, 24, 182, 10.1002/(SICI)1098-2396(199610)24:2<182::AID-SYN10>3.0.CO;2-0 · DOI
  31. Ho, 2005, Am J Psychiatry, 162, 1527, 10.1176/appi.ajp.162.8.1527 · DOI
  32. Hori, 2000, Neurosci Lett, 280, 53, 10.1016/S0304-3940(99)00991-X · DOI
  33. Ito, 2002, Pharmacol Biochem Behav, 65, 705, 10.1016/S0091-3057(99)00263-4 · DOI
  34. Javitt, 1991, Am J Psychiatry, 148, 1301, 10.1176/ajp.148.10.1301 · DOI · Paper page
  35. Jentsch, 1997, Science, 277, 953, 10.1126/science.277.5328.953 · DOI · Paper page
  36. Jentsch, 1998, Neuropsychopharmacology, 19, 105, 10.1016/S0893-133X(98)00004-9 · DOI · Paper page
  37. Kalivas, 1993a, J Neurosci, 13, 266, 10.1523/JNEUROSCI.13-01-00266.1993 · DOI · Paper page
  38. Kalivas, 1993b, J Neurosci, 13, 276, 10.1523/JNEUROSCI.13-01-00276.1993 · DOI · Paper page
  39. Keilhoff, 2004, Biol Psychiatry, 56, 317, 10.1016/j.biopsych.2004.06.010 · DOI
  40. Kempermann, 2003, Biol Psychiatry, 54, 499, 10.1016/S0006-3223(03)00319-6 · DOI · Paper page
  41. Kempermann, 2004a, Trends Neurosci, 27, 447, 10.1016/j.tins.2004.05.013 · DOI · Paper page
  42. Kempermann, 2004b, Curr Opin Neurobiol, 14, 186, 10.1016/j.conb.2004.03.001 · DOI · Paper page
  43. Kitamura, 2003, Neurosci Res, 47, 55, 10.1016/S0168-0102(03)00171-8 · DOI
  44. Lannes, 1991, Neurosci Lett, 128, 177, 10.1016/0304-3940(91)90255-R · DOI
  45. Lindahl, 2004, Neuropsychopharmacology, 29, 2065, 10.1038/sj.npp.1300485 · DOI
  46. Mackler, 2000, J Neurosci, 20, 6210, 10.1523/JNEUROSCI.20-16-06210.2000 · DOI
  47. Malberg, 2000, J Neurosci, 20, 9104, 10.1523/JNEUROSCI.20-24-09104.2000 · DOI · Paper page
  48. Martin, 1979, Life Sci, 24, 1699, 10.1016/0024-3205(79)90255-8 · DOI
  49. Masuo, 1997, Brain Res Brain Res Protoc, 1, 321, 10.1016/S1385-299X(97)00005-6 · doi:10.1016/s1385-299x(97)00005-6
  50. Murray, 2002, J Psychol, 136, 319, 10.1080/00223980209604159 · DOI · Paper page
  51. Nabeshima, 1984, Pharmacol Biochem Behav, 21, 401, 10.1016/S0091-3057(84)80102-1 · DOI
  52. Nacher, 2001, Eur J Neurosci, 13, 512, 10.1046/j.0953-816x.2000.01424.x · DOI · Paper page
  53. Nicoletti, 1996, Trends Neurosci, 19, 267, 10.1016/S0166-2236(96)20019-0 · DOI · Paper page
  54. Nowakowski, 1989, J Neurocytol, 18, 311, 10.1007/BF01190834 · DOI · Paper page
  55. Olney, 1995, Neuropsychopharmacology, 13, 335, 10.1016/0893-133X(95)00079-S · DOI · Paper page
  56. Pechnick, 1989a, J Pharmacol Exp Ther, 250, 534
  57. Pechnick, 1989b, Eur J Pharmacol, 164, 257, 10.1016/0014-2999(89)90466-4 · DOI
  58. Prickaerts, 2004, Neurobiol Learn Mem, 81, 1, 10.1016/j.nlm.2003.09.001 · DOI
  59. Radley, 2002, Brain Res, 955, 264, 10.1016/S0006-8993(02)03477-7 · DOI · Paper page
  60. Ricci, 2004, Pharmacol Biochem Behav, 77, 415, 10.1016/j.pbb.2003.10.005 · DOI
  61. Ritz, 1990, Life Sci, 46, 635, 10.1016/0024-3205(90)90132-B · DOI · Paper page
  62. Seki, 2003, Anat Sci Int, 78, 69, 10.1046/j.0022-7722.2003.00043.x · DOI
  63. Smith, 1977, Biochem Pharmacol, 26, 1435, 10.1016/0006-2952(77)90370-7 · DOI · Paper page
  64. Snyder, 1980, Nature, 285, 355, 10.1038/285355a0 · DOI · Paper page
  65. Steinpreis, 1993, Brain Res, 612, 263, 10.1016/0006-8993(93)91671-E · DOI
  66. Sturgeon, 1979, Eur J Pharmacol, 59, 169, 10.1016/0014-2999(79)90279-6 · DOI · Paper page
  67. Sturgeon, 1982, Psychopharmacology, 76, 52, 10.1007/BF00430755 · DOI
  68. Suzuki, 2000, Synapse, 38, 198, 10.1002/1098-2396(200011)38:2<198::AID-SYN11>3.0.CO;2-K · DOI
  69. Tani, 2001, Br J Pharmacol, 134, 1411, 10.1038/sj.bjp.0704370 · doi:10.1038/sj.bjp.0704370
  70. Teuchert-Noodt, 2000, J Neural Transm, 107, 133, 10.1007/s007020050012 · DOI
  71. Tsai, 1995, Arch Gen Psychiat, 52, 829, 10.1001/archpsyc.1995.03950220039008 · DOI · Paper page
  72. Ujike, 1990, Psychopharmacology, 102, 459, 10.1007/BF02247125 · DOI
  73. Wakade, 2002, J Neurosci Res, 69, 72, 10.1002/jnr.10281 · DOI · Paper page
  74. Walker, 2002, Am J Psychiatry, 159, 821, 10.1176/appi.ajp.159.5.821 · DOI · Paper page
  75. Wang, 1999, J Neurosci Res, 55, 762, 10.1002/(SICI)1097-4547(19990315)55:6<762::AID-JNR10>3.0.CO;2-E · DOI
  76. Wang, 2004, Neuropsychopharmacology, 29, 1230, 10.1038/sj.npp.1300449 · DOI · Paper page
  77. Wang, 1997, J Neurosci, 17, 5993, 10.1523/JNEUROSCI.17-15-05993.1997 · DOI
  78. Yamaguchi, 2002, Synapse, 58, 63, 10.1002/syn.20182 · DOI
  79. Yoshida, 1988, Experientia, 44, 700, 10.1007/BF01941033 · doi:10.1007/bf01941033
  80. Yu, 2002, Neuroscience, 113, 1, 10.1016/S0306-4522(02)00163-X · DOI

Cited by

Metadata

Authors
Liu, J., Suzuki, T., Seki, T., Namba, T., Tanimura, A., & Arai, H.
Venue
Synapse
Publisher
Wiley
Published
2006
Volume
60
Issue
1
Pages
56-68
ISSN
  • 0887-4476 (ISSN-L)
  • 1098-2396
OpenAlex
W1973429276
Cited by
52
References
10
FWCI
1.37
Type
journal article
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 3530 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.